Arkolith/Insider Trading/LYEL/Form 4

Seely Lynn

President and CEO, DirectorLyell Immunopharma, Inc. (LYEL) · full profile →Form 4 · filed Feb 26, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 10, 2025Grant(A)338K—$0538K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 10, 2025Grant(A)1.4M—$01.4M
Feb 10, 2025Grant(A)169K—$0169K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-005768) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML